205 related articles for article (PubMed ID: 25211269)
21. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
[TBL] [Abstract][Full Text] [Related]
22. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H
World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603
[TBL] [Abstract][Full Text] [Related]
23. Survival benefits of adjuvant chemotherapy for patients with residual pathologic disease after neoadjuvant chemotherapy and surgery for locally advanced esophageal squamous cell carcinoma.
Lu H; Liu JF; Rong Y; Liu XB; Wang Y
J Gastrointest Surg; 2024 Jun; 28(6):867-869. PubMed ID: 38570232
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Relevance of Lymph Node Regression After Neoadjuvant Chemoradiation for Esophageal Cancer.
Philippron A; Bollschweiler E; Kunikata A; Plum P; Schmidt C; Favi F; Drebber U; Hölscher AH
Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):549-558. PubMed ID: 28043475
[TBL] [Abstract][Full Text] [Related]
25. Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.
Okamura A; Watanabe M; Mine S; Kurogochi T; Yamashita K; Hayami M; Imamura Y; Ogura M; Ichimura T; Takahari D; Chin K
Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859367
[TBL] [Abstract][Full Text] [Related]
26. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
[TBL] [Abstract][Full Text] [Related]
27. Clinical Significance of
Hamai Y; Hihara J; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Nagata Y; Aoki Y; Furukawa T; Okada M
Ann Surg Oncol; 2019 Jun; 26(6):1869-1878. PubMed ID: 30675704
[TBL] [Abstract][Full Text] [Related]
28. [Patterns of recurrence in patients with stage pT3N0M0 thoracic esophageal squamous cell carcinoma after two-field esophagectomy].
Wang Y; Wang L; Yang Q; Li J; He M; Yao J; Qi Z; Li B; Qiao X
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):48-54. PubMed ID: 26796807
[TBL] [Abstract][Full Text] [Related]
29. The prognostic value of metastatic lymph node number and ratio in oesophageal squamous cell carcinoma patients with or without neoadjuvant chemoradiation.
Chien HC; Chen HS; Wu SC; Hsu PK; Liu CY; Wang BY; Shih CH; Liu CC
Eur J Cardiothorac Surg; 2016 Aug; 50(2):337-43. PubMed ID: 26893382
[TBL] [Abstract][Full Text] [Related]
30. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
Lyu X; Huang J; Mao Y; Liu Y; Feng Q; Shao K; Gao S; Jiang Y; Wang J; He J
J Surg Oncol; 2014 Dec; 110(7):864-8. PubMed ID: 24976079
[TBL] [Abstract][Full Text] [Related]
32. Controlling lymph node micrometastases by neoadjuvant chemotherapy affects the prognosis in advanced esophageal squamous cell carcinoma.
Hiraki Y; Kimura Y; Imano M; Kato H; Iwama M; Shiraishi O; Yasuda A; Shinkai M; Makino T; Motoori M; Yamasaki M; Miyata H; Satou T; Satoh T; Furukawa H; Yano M; Doki Y; Yasuda T
Surg Today; 2021 Jan; 51(1):118-126. PubMed ID: 32596796
[TBL] [Abstract][Full Text] [Related]
33. Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent.
Honma Y; Hokamura N; Nagashima K; Sudo K; Shoji H; Iwasa S; Takashima A; Kato K; Hamaguchi T; Boku N; Umezawa R; Ito Y; Itami J; Koyanagi K; Igaki H; Tachimori Y
Anticancer Res; 2017 Jul; 37(7):3741-3749. PubMed ID: 28668869
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
Yasuda T; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Doki Y
Ann Surg Oncol; 2015 Aug; 22(8):2599-607. PubMed ID: 25524011
[TBL] [Abstract][Full Text] [Related]
35. The usefulness of neoadjuvant chemoradiation therapy for locally advanced esophageal cancer with multiple lymph-node metastases.
Okumura H; Uchikado Y; Omoto I; Kita Y; Sasaki K; Arigami T; Uenosono Y; Matsushita D; Hiraki Y; Owaki T; Ishigami S; Natsugoe S
Ann Surg Oncol; 2014 Sep; 21(9):2845-9. PubMed ID: 24728820
[TBL] [Abstract][Full Text] [Related]
36. A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Nakajima Y; Kawada K; Tokairin Y; Hoshino A; Okada T; Kawano T
Dig Surg; 2018; 35(2):131-137. PubMed ID: 28554183
[TBL] [Abstract][Full Text] [Related]
37. Use of (18)F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma.
Makino T; Doki Y; Miyata H; Yasuda T; Yamasaki M; Fujiwara Y; Takiguchi S; Higuchi I; Hatazawa J; Monden M
Surgery; 2008 Nov; 144(5):793-802. PubMed ID: 19081023
[TBL] [Abstract][Full Text] [Related]
38. Current Advancement in Multidisciplinary Treatment for Resectable cStage II/III Esophageal Squamous Cell Carcinoma in Japan.
Matsuda S; Takeuchi H; Kawakubo H; Ando N; Kitagawa Y
Ann Thorac Cardiovasc Surg; 2016 Oct; 22(5):275-283. PubMed ID: 27384595
[TBL] [Abstract][Full Text] [Related]
39. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
[TBL] [Abstract][Full Text] [Related]
40. Lymph node ratio-based staging system for esophageal squamous cell carcinoma.
Chen SB; Weng HR; Wang G; Zou XF; Liu DT; Chen YP; Zhang H
World J Gastroenterol; 2015 Jun; 21(24):7514-21. PubMed ID: 26139998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
